Has Neil Julie, MD received payments from drug or device companies?

Yes. Drug and device makers reported $7,533 in general payments to Neil Julie, MD across 217 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Neil Julie, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Neil Julie, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Neil Julie, MD

Gastroenterology · Rockville, MDNPI 1578661054

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (53.1%), food and beverage and education — rather than concentrated in one kind of arrangement. AbbVie accounts for 61.8% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2019 at $3,801 and has fallen 87.9% since, to $461 in 2025.

$7,533in general payments, 2019–2025

Across 217 payments — averaging $34.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$5K
Gilead$753
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$617
Bristol Myers Squibb$275
Pfizer$226
Intercept Pharmaceuticals, Inc.$177
plus $830 from 15 others

$1,610in research payments, 2019–2025

Across 1 payment — averaging $1610.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Novartis$2K

What the payments were for

Speaking & faculty fees$4,00053%
Food & beverage$3,30144%
Education$2323%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie(2 entities)	42	$4,655
Gilead	38	$753
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	59	$617
Bristol Myers Squibb	28	$275
Pfizer	6	$226
Intercept Pharmaceuticals, Inc.	10	$177
Ardelyx, Inc.	1	$136
E.r. Squibb & Sons, L.L.C.	1	$104
Nestle Healthcare Nutrition Inc.	5	$93
Ironwood Pharmaceuticals, Inc	5	$71
Takeda Pharmaceuticals U.S.A., Inc.	4	$70
Johnson & Johnson	4	$60
Regeneron Healthcare Solutions, Inc.	3	$56
Ipsen Biopharmaceuticals, Inc	2	$51
Madrigal Pharmaceuticals	2	$50
Braintree Laboratories, Inc.	2	$37
Aimmune Therapeutics, Inc.	1	$33
Lilly USA, LLC	1	$20
Echosens North America, Inc.	1	$20
Phathom Pharmaceuticals, Inc.	1	$17
Intra-sana Laboratories	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

LINZESS$4,000
VIBERZI$1,320
IBSRELA$136
XELJANZ$125
ZEPOSIA$104

How this compares

$7,533 in reported general payments places this provider in the 75th percentile of 455 gastroenterology providers in Maryland.

See all gastroenterology providers in Maryland →

Medicare billing

Part B allowed, 2024

$72,992

Medicare patients

239

Services billed

458

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Ursodiol	17	$3,725
Budesonide EcBudesonide	14	$3,011
Klor-ConPotassium Chloride	11	$2,258
Rabeprazole Sodium	22	$1,640
Famotidine	55	$1,096
Pantoprazole Sodium	66	$869
Dicyclomine Hcl	16	$750
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates	13	$695
Omeprazole	39	$645
Budesonide DrBudesonide	11	$526
Ondansetron Hcl	11	$342
Metoclopramide Hcl	21	$184

Paid to pharmacies, not to this prescriber.

Other gastroenterology in Rockville

Apurva ModiRockville$1.1M
Sergey KantsevoyBaltimore$1.1M
Anurag MaheshwariBaltimore$803K
Aline Charabaty PishvaianBaltimore$631K
Zachary BormanChevy Chase$520K
Mouen KhashabBaltimore$440K
Erica CohenChevy Chase$385K
Natarajan RavendhranCatonsville$367K
Raymond CrossBaltimore$341K
Raja TaunkAnnapolis$328K

See the full list for Maryland →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →